45
Participants
Start Date
August 17, 2020
Primary Completion Date
August 31, 2025
Study Completion Date
August 31, 2025
DMAB Discontinuation and Switching
"Investigators will test the hypothesis that an increase in bone turnover markers (e.g. CTX and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to late zoledronic acid (9 months after last denosumab dose) compared to participants randomized to early zoledronic acid (6 months after last denosumab dose) or weekly alendronate (6 months after last denosumab dose"
University of Alabama at Birmingham, Birmingham
Collaborators (1)
Maastricht University
OTHER
Vrije Universiteit Brussel
OTHER
Amgen
INDUSTRY
University of Alabama at Birmingham
OTHER